Neoadjuvant trastuzumab deruxtecan combination therapy reduces the residual cancer burden in high-risk early breast cancer, even if a pathologic complete response is not achieved, shows analysis.

High School DxD Season 3 was notably the final season produced under TNK, and more notably featured some material that was not from the original light novel releases. High School DxD Hero then finally ...

If you hadn’t heard, High School DxD is back and bouncier than ever. The series made its return this month with its fourth season, and fans have been waiting to reunite with Issei and his devilish ...

Patterns of immune-related adverse events (irAEs) in adolescent and young adult (AYA) patients with melanoma receiving immune checkpoint inhibitors (ICIs). T-DXd 5.4 mg/kg discontinuation, dose ...

The FDA has approved trastuzumab deruxtecan (T-DXd; Enhertu, Daiichi Sankyo/AstraZeneca) in combination with pertuzumab for the first-line treatment of unresectable or metastatic HER2-positive breast ...

In the article that accompanies this editorial, Rugo et al 5 review the real-world practices for the management of T-DXd–related ILD in breast cancer, providing helpful advice on strategies aimed at ...